The latest weapon in the battle against cancer is showing promising results — and it's a growing opportunity for investors, according to Redburn Atlantic. Radiopharmaceuticals are used to detect and treat the disease. They have also helped provided more accurate diagnoses and a way to attack tumors without damaging healthy cells. Big pharma is betting billions on the treatments, with a number of acquisitions in the space in recent years.
mountain GE Healthcare's one-year performance "We expect the company to be able to deliver strong improvements in profitability, supported by operational leverage, improving mix — led by accelerating growth in radiopharmaceuticals — and an extensive efficiency programme," he wrote. Meanwhile, Ridley-Day initiated coverage last week on Lantheus with a buy rating and $175 price target, suggesting nearly 72% upside from Wednesday's close.
mountain Lantheus Holding's one-year performance The company is a leading supplier of radiopharma diagnostic agents and is also moving into radiopharma therapeutics. It has a "strong pipeline of radionuclides for both diagnosis and therapy," he said. "Lantheus benefits from its focus on this rapidly expanding market, with 78% of revenues from radiopharmaceuticals and related products," Ridley-Day added.